Document:

Exhibit 10.8

 

Amendment 2 to Exclusive License Agreement
between

Checkpoint Therapeutics, Inc. and Dana-Farber
Cancer Institute, Inc.

 

This second amendment (“Amendment
2”), made effective as of April 12, 2016 (“Amendment 2 Effective Date”), is between the Dana-Farber Cancer Institute,
Inc., a Massachusetts non-profit organization having offices at 450 Brookline Avenue, Boston, MA 02215 (“DFCI”), and
Checkpoint Therapeutics, Inc., a Delaware corporation with offices at 3 Columbus Circle, New York, NY 10019 (“CTI”),
collectively the “Parties” with reference to the following:

 

WHEREAS, DFCI and CTI entered into an Exclusive
License Agreement made effective as of March 2, 2015 and amended as of October 5, 2015 (collectively, “Agreement”)
covering intellectual property developed in the laboratory of Dr. Wayne Marasco at DFCI with respect to PD-L1, GITR and CAIX antibodies;

 

WHEREAS, the Parties now wish to add additional
GITR antibodies, know-how and intellectual property developed in the laboratory of Dr. Wayne Marasco to the DFCI Technology licensed
under the original Agreement, and include additional fees in consideration thereof;

 

WHEREAS, the Parties hereto agree that
this Amendment 2 is hereby made an integral part of the Agreement, incorporated therein by this reference;

 

WHEREAS, capitalized terms used herein
and not otherwise defined shall have the respective meanings assigned to such terms in the Agreement;

 

NOW, THEREFORE, in consideration of the
premises contained herein and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties
hereto agree as follows:

 

		1.	Schedules 2 (DFCI Know-How) and 4 (DFCI Antibodies) are hereby amended to include intellectual
property, know-how and GITR Antibodies pertaining to DFCI C2195, developed in the laboratory of Dr. Wayne Marasco, and more specifically
described in Exhibit A, which is incorporated herein by reference and attached hereto.

 

		2.	Article 3.2c (Milestone Dates for a Licensed Product Targeting GITR) is hereby amended to
include the following additional diligence milestone:

 

	Milestone	Achievement Date
	Developability Assessment	One hundred eighty (180) days from the Amendment 2 Effective Date

 

“Developability Assessment”
means in-silico or in-vitro assessment of affinity, productivity, aggregation, stability, heterogeneity, solubility, viscosity,
and potential for immunogenicity of an antibody sequence or protein included in this Amendment 2.

 

		3.	Article 5 (Financial Provisions) is hereby amended to include the following payments, in
consideration of the additional rights granted by DFCI to CTI under this Amendment 2:

 

		a.	Amendment Upfront Fee. A non-creditable, non-refundable Amendment Upfront Fee in the sum
of ten thousand U.S. dollars ($10,000) shall be due and payable by CTI to DFCI upon execution of this Amendment 2.

 

		b.	Developability Assessment Milestone Payment.  Upon conclusion of the one hundred eighty
(180) day Developability Assessment period, CTI shall pay to DFCI a Milestone Payment in the sum of one hundred thousand U.S. dollars
($100,000) if CTI elects to continue with research and clinical development of Antibodies
containing any fragment, variant, derivative, or improvement of the novel GITR antibodies contained hereunder in Exhibit A.

 

    	1 

     

    

 

		4.	Article 10 (Term and Termination) is hereby amended to include the following termination
provision:

 

		a.	Amendment 2 Termination. Upon conclusion of the one hundred eighty (180) day Developability
Assessment period, if CTI elects not to continue with research and clinical development of Antibodies containing any fragment,
variant, derivative, or improvement of the novel GITR antibodies contained hereunder in Exhibit A, this Amendment 2 shall immediately
terminate.

 

Except as amended above, all other terms
and conditions of the Agreement shall remain unchanged and in full force and effect.

 

IN WITNESS WHEREOF, the Parties hereto have caused this Amendment
2 to be duly executed by their respective authorized representatives.

 

	Dana-Farber Cancer Institute, Inc. 	 	Checkpoint Therapeutics, Inc.
	 	 	 	 	 
	 	 	 	 	 
	By: 	/s/ Gary M. Sclar	 	By: 	/s/ James Oliviero
	 	 	 	 	 
	Name: 	Gary M. Sclar, JD	 	Name:   	James Oliviero
	 	 	 	 	 
	Title: 	Chief Research Business
Dev Officer, Interim	 	Title: 	President & CEO
	 	 	 	 	 
	Date: 	4/12/16 	 	Date: 	4/12/2016

  

    	2 

     

    

 

EXHIBIT A

 

DFCI Invention #C2195 entitled “Isolation
of new Human Anti-GITR monoclonal antibodies by phage display”:

 

We used the extensively validated Mehta
I/II human antibody-phage display libraries to pan against human GITR for the purpose of isolating new human anti-GITR mAbs. We
have identified circa 40 antibodies that bind to GITR. Their DNA and amino acid sequences have been determined, as well as their
relative affinities.

 

    	3Exhibit  10.9

 

Amendment 3 to Exclusive License Agreement
between

Checkpoint Therapeutics, Inc. and Dana-Farber
Cancer Institute, Inc.

 

This third amendment (“Amendment
3”), made effective as of October 24, 2016 (“Amendment 3 Effective Date”), is between the Dana-Farber Cancer
Institute, Inc., a Massachusetts non-profit organization having offices at 450 Brookline Avenue, Boston, MA 02215 (“DFCI”),
and Checkpoint Therapeutics, Inc., a Delaware corporation with offices at 2 Gansevoort Street | 9th Floor, New York NY 10014 (“CTI”),
collectively the “Parties” with reference to the following:

 

WHEREAS, DFCI and CTI entered into an Exclusive
License Agreement made effective as of March 2, 2015 and amended as of October 5, 2015 (Amendment 1) and April 12, 2016 (Amendment
2) (all three collectively, “Agreement”) covering intellectual property developed in the laboratory of Dr. Wayne Marasco
at DFCI with respect to PD-L1, GITR and CAIX antibodies;

 

WHEREAS, the Parties wish to include the
title of the patent application referenced and to name the corresponding provisional patent applications;

 

WHEREAS, the Parties hereto agree that
this Amendment 3 is hereby made an integral part of the Agreement, incorporated therein by this reference;

 

NOW, THEREFORE, in consideration of the
premises contained herein and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties
hereto agree as follows:

 

Exhibit A of Amendment 2 is hereby amended to read in full,
as indented below:

 

EXHIBIT A

 

DFCI Invention #C2195 entitled
“Isolation of new Human Anti-GITR monoclonal antibodies by phage display”:

 

The Marasco lab used the extensively
validated Mehta I/II human antibody-phage display libraries to pan against human GITR for the purpose of isolating new human anti-GITR
mAbs., and has identified circa 40 antibodies that bind to GITR. Their DNA and amino acid sequences have been determined, as well
as their relative affinities.

 

The title of the corresponding
patent applications filed is “GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) ANTIBODIES AND METHODS OF USE
THEREOF.” The licensed patent rights include provisional application serial number 62/365,712, filed July 22, 2016 (DFCI-0141/PO1US;
322270-2613) and provisional application serial number 62/375,634, filed August 16, 2016 (DFCI-0141/PO2US; 322270-2621) and any
convention date filings and subsequent domestic or foreign counterparts thereof claiming the benefit of their respective priority
dates.

 

 

Except as amended above, all other terms
and conditions of the Agreement shall remain unchanged and in full force and effect.

 

IN WITNESS WHEREOF, the Parties hereto have caused this Amendment 3 to be duly executed by their respective
authorized representatives.

 

    1 

     

    

	
        Dana-Farber Cancer Institute, Inc. 

         
	 	Checkpoint Therapeutics, Inc.
	 	 	 	 	 
	 	 	 	 	 
	By: 	/s/ Gary M. Sclar	 	By: 	/s/ James Oliviero
	 	 	 	 	 
	Name: 	Gary M. Sclar, JD	 	Name: 	James Oliviero
	 	 	 	 	 
	Title: 	Vice President, Dana-Farber Innovations	 	Title: 	President and CEO
	 	 	 	 	 
	Date: 	10/24/16	 	Date: 	11/3/2016 

  

    2Exhibit  10.11

 

FIRST AMENDMENT TO

LICENSE AGREEMENT

 

This First Amendment
to License Agreement (the “Amendment”) is effective as of February 21, 2017 and amends that certain License
Agreement, dated March 17, 2015, (the “Agreement”) by and between NeuPharma, Inc. (“Licensor”)
and Checkpoint Therapeutics, Inc. (“Checkpoint”). Licensor and Checkpoint are each referred to individually
as a “Party” and together as the “Parties.”

 

BACKGROUND

 

A. Licensor and Fortress Biotech, Inc. (f/k/a
Coronado Biosciences, Inc.) (“Fortress”) entered into the Agreement.

 

B. Fortress subsequently assigned to Checkpoint
all of its right, title and interest in and to the Agreement pursuant to an Assignment and Assumption Agreement dated March, 17,
2015.

 

C. Checkpoint and Licensor now wish to amend
the Agreement as provided herein.

 

NOW THEREFORE, in
consideration of the mutual covenants and agreements contained herein, the sufficiency of which is acknowledged by both Parties,
the Parties agree as follows:

 

		1.	Definitions. Unless otherwise defined in this Amendment,
initially capitalized terms used herein shall have the meanings given to them in the Agreement.

 

		2.	Amendments. 

 

		a)	The introductory paragraph of the Agreement shall be amended by
deleting “Coronado Biosciences, Inc., a Delaware corporation with its place of business at 3 Columbus Circle, 15th Floor,
New York, New York 10019 (“Coronado”)” and replacing it with the following:

 

“Checkpoint
Therapeutics, Inc., a Delaware corporation with its place of business at 2 Gansevoort Street, 9th Floor, New York,
NY 10014 (“Checkpoint”)

 

		b)	The Agreement shall be amended by deleting all references to Coronado
and replacing them with “Checkpoint.”

 

		c)	The Agreement shall be amended by adding the following new paragraph
as the second paragraph of Section 2.1:

 

“Without limiting the rights granted to Checkpoint
in the foregoing paragraph, Licensor hereby grants to Checkpoint and its Affiliates, and Checkpoint and its Affiliates hereby accept,
a nonexclusive, royalty-free right and license (with the right to sublicense through multiple tiers of sublicensees in accordance
with the provisions of Section 2.2) under the Licensor Technology to Develop and have Developed the Licensed Products in and for
the Field in Thailand, and to import and use the Licensed Products in Thailand in connection with such Development.”

 

    	1 

     

    

 

		d)	Article III of the Agreement shall be amended by adding the following
new Section 3.8:

 

“3.8Clinical
Studies in Thailand. Notwithstanding anything to the contrary in this Agreement, Checkpoint shall (i) have sole responsibility
for, and control over, clinical studies involving a Licensed Product that it sponsors in Thailand (including, without limitation
clinical monitoring, provision of reports and communications with Regulatory Authorities) (the “Thailand Study(ies)”),
(ii) provide Licensor with a copy of any final clinical study report that Checkpoint possesses for each such Thailand Study; (iii)
own all Regulatory Filings in Thailand relating to Thailand Studies; and (iv) notify Licensor of Adverse Events and Serious Adverse
Events occurring with respect to Thailand Studies in accordance with Section 4.5 hereof.

 

Notwithstanding the foregoing, upon (i) Checkpoint determining
that it has completed any Thailand Study with respect to a Licensed Product, and (ii) written request by Licensor, Checkpoint shall,
to the extent permitted by applicable laws, rules and regulations, use commercially reasonable efforts to transfer ownership of
all Regulatory Filings in Thailand pertaining solely to such Thailand Studies to Licensor, provided that Licensor first agrees
in writing to assume all obligations and liabilities associated with such Regulatory Filings. Prior to such assignment and assumption
of Regulatory Filings, Licensor shall have a right of reference to such Regulatory Filings for use in the Licensor Territory, and
following such assignment and assumption of Regulatory Filings, Licensor shall be entitled to use any such Regulatory Filings in
the Licensor Territory. Checkpoint and its Sublicensees shall retain a right of reference to any such Regulatory Filing that is
assigned to Licensor solely for use in the Territory.

 

To
the extent permitted by applicable laws, rules and regulations, Checkpoint shall use commercially reasonable efforts to: (i) allow
Licensor to be present at Checkpoint-attended meetings or teleconferences with Regulatory Authorities in Thailand, clinical investigators,
or contract research organizations (“CRO(s)”) contracted by Checkpoint for Thailand Studies that Licensor in its sole
discretion determines are material to the Development of the Licensed Product, provided that (a) such meetings or teleconferences
pertain to Thailand Studies, (b) Licensor shall not actively participate (i.e., Licensor shall be an observer) in such meetings
or teleconferences unless pre-approved in writing by Checkpoint, (ii) provide Licensor with periodic reports, by electronic mail
or teleconferences, no less frequently than monthly, regarding Thailand Studies, which reports shall include data and findings
in Checkpoint’s possession related to the Thailand Studies, (iii) promptly provide, but in no case less than ten (10) business
days from Checkpoint’s receipt thereof, Licensor with copies of all communications it or its CRO provides to and receives
from Regulatory Authorities in Thailand with respect to the Thailand Studies; and (iv) upon Licensor’s request, provide Licensor
with view-only access to any clinical database for the Thailand Studies whether maintained by Checkpoint or any third party (including
any CRO) on behalf of Checkpoint. Nothing in this Section 3.8 shall be deemed to provide Licensor with any authority or decision-making
power regarding the Thailand Studies, which authority and decision-making power shall be retained solely by Checkpoint, provided
that Checkpoint will consider in good faith comments and suggestions made by Licensor with respect to the Thailand Studies. For
the avoidance of doubt, all information regarding the Thailand Studies shall be deemed Checkpoint’s Confidential Information,
subject to Licensor’s right of reference to Regulatory Filings in Thailand for use in the Licensor Territory; provided, however,
that upon assignment of Regulatory Filings in Thailand to Licensor as provided in Section 3.8, all information related to the applicable
Thailand Studies shall be deemed both Parties’ Confidential Information (“Joint Information”). 

 

    	2 

     

    

 

Notwithstanding
anything to the contrary in this Agreement following such assignment, each Party shall have the right to: 

 

(a)
use and disclose Joint Information in connection with: (i) researching, Developing, having Developed, manufacturing, having manufactured,
using, importing and Commercializing and having Commercialized the Licensed Products in the Field and in such Party’s respective
territory (i.e., the Territory for Checkpoint and Licensor Territory for Licensor); (ii) complying with applicable laws, rules
and regulations, (iii) filing, prosecuting, defending or otherwise obtaining and maintaining patents, and (iv) publishing the results
of the applicable Thailand Studies; and 

 

(b)
without limiting the generality of the immediately preceding clause (a), disclose Joint Information: to (w) its Affiliates, (x)
Third Parties involved or potentially involved in the research, Development, manufacture, use, or Commercialization of the Licensed
Product (who may then further disclose the Joint Information to other such Third Parties), (y) its or its Affiliate’s actual
or bona fide potential collaborators, manufacturers, licensees, licensors, sublicensees, investors, acquirers, merger or acquisition
candidates, partners, lenders or financing sources, in each case for use of such information for business purposes relating to
this Agreement or for due diligence in connection with potential development, manufacturing, commercialization, licensing, investment,
merger or acquisition, loan or financing transactions and (z) Regulatory Authorities in such Party’s respective territory
(i.e., the Territory for Checkpoint and Licensor Territory for Licensor) in connection with the research, Development, manufacture,
use, or Commercialization of the Licensed Products.”

 

		e)	The first sentence of Section 4.5 shall be amended to add the
following new clause at the end:

 

“, provided, however, that Licensor shall not
have such responsibility with respect to clinical studies involving a Licensed Product that Checkpoint sponsors in Thailand.”

 

		f)	Section 10.4(e) of the Agreement shall be amended to add the following
new clause at the end:

 

“;
provided, however, that the transfer of any Regulatory Filings from any Thailand Studies shall not be contingent upon such written
agreement, and shall be transferred to Licensor immediately on termination without payment or royalty obligation on Licensor. 

 

		g)	Section 11.8 of the Agreement shall be amended to delete Checkpoint’s
notice address and replace it with the following:

 

“Checkpoint
Therapeutics, Inc. 

2 Gansevoort Street

9th Floor

New York, NY 10014

Attention: President”

 

    	3 

     

    

 

		3.	No Other Modifications. Except as specifically set
forth in this Amendment, the terms and conditions of the Agreement shall remain in full force and effect. No waiver of the performance
of any obligation under this Amendment shall be effective unless it has been given in writing and signed by the Party giving such
waiver. No provision of this Amendment may be amended or modified other than by a written document signed by authorized representatives
of each Party.

 

THIS
AMENDMENT AND THE AGREEMENT AS AMENDED BY THIS AMENDMENT SET FORTH THE ENTIRE AGREEMENT AND UNDERSTANDING OF THE PARTIES WITH RESPECT
TO THE SUBJECT MATTER HEREOF, AND SUPERCEDES ALL PRIOR DISCUSSIONS, AGREEMENTS AND WRITINGS IN RELATION THERETO.

 

		4.	Miscellaneous. This Amendment may be executed in
two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. 

 

 

IN WITNESS WHEREOF,
the Parties intending to be bound have caused this Amendment to be executed by their duly authorized representatives.

 

 

CHECKPOINT
THERAPEUTICS, INC.

 

	By: 	/s/ James Oliviero 	 
	Name: 	James Oliviero 	  
	Title: 	CEO 	 

 

 

NEUPHARMA, INC.

 

	By: 	/s/ Shawn Qian 	 
	Name: 	Shawn Qian 	  
	Title: 	CEO 	 

 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]